Summary
Although prostacyclin (PGI2) has been shown to exert a protective effect on ischaemic hearts its precise mode of action remains obscure. Possible explanations include protection of the high energy phosphate stores (ATP and CP), maintenance of homeostasis with respect to Ca2+, and an antiaggregatory effect. The following experiments were undertaken to investigate these possibilities, using isolated, spontaneously beating rat hearts perfused with Krebs-Henseleit solution. Ischaemia was induced at 37°C for 30 min by reducing the flow rate from 10.0 to 0.1 ml/min, and was followed by reperfusion. PGI2 was given as a constant infusion (20 ng/ml). The hearts were frozen and assayed for ATP and CP, or digested in HNO3 and assayed for Ca2+. Peak developed tension was recorded throughout. The results show that PGI2 slowed the rate of decline of developed tension during low flow perfusion, and hastened the recovery of contractions on reperfusion. These effects could not be accounted for in terms of an improved supply of ATP or CP, or an altered tissue Ca2+. The protective effect of PGI2 on isolated, buffer-perfused hearts may be a reflection of a generalized, but underfined, mechanism of cell preservation which has also been observed in other systems.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Apstein CS, Ahn J, Brent BN, Briggs L, Shapiro HM (1970) Ischemic “pump” failure: evidence for a mechanical, non-metabolic initial cause. Circulation 60:II, p 114
Araki H, Lefer AM (1980) Cytoprotective actions of prostacyclin during hypoxia in the isolated perfused cat liver. Am J Physiol 238:176–181
Araki H, Lefer AM (1980) Role of prostacyclin in the preservation of ischaemic myocardial tissue in the perfused cat heart. Circ Res 47:757–763
Berger HJ, Zaret BL, Speroff L, Cohen LS, Wolfson S (1977) Cardiac prostaglandin release during myocardial ischaemia induced by atrial pacing in patients with coronary artery disease. Am J Cardiol 39:481–486
Bunting S, Gryglewski RJ, Moncada S, Vane JR (1976) Arterial walls generate from prostaglandin endoperoxides a substance which relaxes strips of mesenteric and coelic arteries and inhibits platelet aggregation. Prostaglandins 12:897–913
Coker SJ, Parratt JR (1981) Prostacyclin-induced changes in coronary blood flow and oxygen handling in the normal and acutely ischaemic canine myocardium. Bas Res Cardiol 76:457–462
Coker SJ, Parratt JR, Ledingham IMcA, Zeitlin IJ (1981) Thromboxane and prostacyclin release from ischaemic myocardium in relation to arrhythmias. Nature 291:323–324
Dusting GJ, Moncada S, Vane JR (1979) Prostaglandins, their intermediates and precursors: Cardiovascular actions and regulatory roles in normal and abnormal circulatory systems. Prog in Cardiovasc Dis 21:405–430.
Ellis EF, Oetz O, Roberts LJ, Payne NA, Sweetman BJ, Nies AS, Oates JA (1976) Coronary arterial smooth muscle contraction by a substance released from platelets: evidence that it is thromboxane A2. Science 193:1135–1137
Hamberg M, Svensson J, Samuelsson B (1975) Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 72:2994–2998
Jugdutt BI, Becker LC (1981) Prostaglandin inhibition and myocardial infarct size. Clin Cardiol 4: 117–124
Lefer AM, Ogletree ML, Smith JB, Silver MJ, Nicolaou KC, Barnette WE, Gasic GP (1978) Prostacyclin: a potentially valuable agent for preserving myocardial tissue in acute myocardial ischemia. Science 200:52–54
Moncada S (1982) Biological importance of prostacyclin. Brit J Pharm 76:3–31
Nayler WG, Ferrari R, Poole-Wilson PA, Yepez CE (1979) A protective effect of a mild acidosis on hypoxic heart muscle. J Mol Cell Cardiol 11:1053–1071
Nayler WG, Ferrari R, Williams A (1980) Protective effect of pretreatment with verapamil, nifedipine and propranolol on mitochondrial function in the ischemic and reperfused myocardium. Am J Cardiol 46:242–248
Nayler WG, Scott EM (1982) The effect of chemical sympathectomy on mitochondrial function in the ischaemic and reperfused myocardium. Brit J Pharm 77:707–715
Ogletree ML, Flynn JT, Feola M, Lefer AM (1977) Early prostaglandin release from ischaemic myocardium in the dog. Surg Gynecol Obstetr 144:734–740
Ogletree ML, Lefer AM, Smith JB, Nicolaou KS (1979) Studies on the protective effect of prostacyclin in acute myocardial ischemia. Eur J Pharm 56:95–103
Ohlendorf R, Perzborn E, Schror K (1980) Prevention of infarction-induced decrease in circulating platelet count by prostacyclin. Thromb Res 19:447–453
Ribeiro LG, Brandon TA, Hopkins DG, Reduto LA, Taylor AA, Miller RR (1981) Prostacyclin in experimental myocardial ischemia: Effects on hemodynamics regional myocardial blood flow, infarct size and mortality. Am J Cardiol 47:835–840
Rosen R, Rosen P, Ohlendorf R, Schror K (1981) Prostacyclin prevents ischemia induced increase of lactate and cyclic AMP in ischemic myocardium. Eur J Pharm 69:489–491
Sakai K, Ito T, Ogawa K (1982) Roles of endogenous prostacyclin and thromboxanc A2 in the ischemic canine heart. J Cardiovasc Pharm 4:129–135
Schaper J, Hehrlein F, Schlepper M, Thiedemann KU (1977) Ultrastructural alteractions during ischemia and reperfusion in human hearts during cardiac surgery. J Mol Cell Cardiol 9:175–189
Wollenberger A, Ristau O, Schoffa G (1960) Eine einfache Technik der extram schnellen Abkühlung größerer Gewebsstücke. Pflüg Arch 270:399–412
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nayler, W.G., Purchase, M. & Dusting, G.J. Effect of prostacyclin infusion during low-flow ischaemia in the isolated perfused rat heart. Basic Res Cardiol 79, 125–134 (1984). https://doi.org/10.1007/BF01908299
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF01908299